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Abstract 
 
The study analyzes exon 15 of the adenomatous polyposis coli gene (APC) in a 49-
year-old male patient with brain metastasis. The primary site was lung carcinoma. PCR 
method and direct DNA sequencing of the metastasis, and autologous lymphocyte samples 
identified the presence of a somatic mutation. The substitution was at position 5883 G to A in 
the metastasis tissue. The mutation was confirmed by RFLP analysis using Msp I 
endonuclease, since the mutation strikes Msp I restriction site. Immunohistochemical analysis 
revealed the lack of protein expression of this tumor suppressor gene. The main molecular 
activator of the wnt pathway, beta-catenin, was expressed, and located in the nucleus. The 
mutation is a silent mutation that might have consequences in the creation of a new splice site. 
Different single-base substitutions in APC exons need not to be evaluated only by the 
predicted change in amino acid sequence, but rather at the nucleotide level itself. In our 
opinion such silent mutations should also be incorporated in mutation detection rate and 
validation.  
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Introduction 
 
One of the most common metastatic sites for lung cancer is the brain. We investigated 
exon 15 of the APC gene in a patient with brain metastasis. The primary site was lung 
carcinoma. The APC gene (chromosome 5q21) is 8535 bp long and is organized in 15 [1] 
translated exons. The gene encodes a large multidomain 2843 amino acid protein that is 
expressed in a number of fetal and adult human tissues [2, 3]. The protein of this tumor 
suppressor gene has many cellular functions: as a component of the wnt signal transduction 
pathway [4, 5], as a component of adherens junctions, and as a component of the cytoskeleton 
stabilization. Mutation analysis of the APC gene revealed more than 400 different germline 
mutations [3, 6] responsible for familial adenomatous polyposis coli (FAP), but the overall 
number of detected mutations, germline and somatic, is more than 700 according to the 
Human Gene Mutation Database [HGMD, http://www.hgmd.org]. The majority of detected 
mutations result in a truncated (shorter) protein product. Novel mutational reports reveal a 
great variety of private mutations [7], and also single-base substitutions that result in silent 
DNA variants having a role in RNA splicing regulation [1].  
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Exon 15 comprises more than 75% of the coding sequence of the APC gene and is the 
most common target for both germline and somatic mutation [3, 8]. Although extensive 
somatic mutations were observed throughout the APC gene, the majority of somatic mutations 
in colon would be clustered within a small region of exon 15, less than 10% of the coding 
region, called mutation cluster region or MCR (from codons 1250 to 1513) [9].  On the other 
hand reports on somatic APC mutations in human tumors other than colon indicate that the 
concept of a mutation cluster region is not applicable to all cancers, for instance breast cancer 
[10]. 
It has been well documented that the APC gene is implicated in tumorigenesis [11-13]. 
The involvement of APC as a general tumor suppressor gene in a great variety of human 
tumors has been known for a long time. Moreover, its involvement in lung cancer is not an 
unknown event. Frequent loss of heterozygosity has been observed in 70-80% of small cell 
lung carcinomas (SCLCs) [14] and in 30-80% of non-small cell lung carcinomas (NSCLCs) 
[15]. Novel reports indicate that APC mutations although infrequent can still be identified in 
lung carcinogenesis [16, 17].  
 
Materials and Methods 
DNA extraction  
A case of brain metastasis, together with autologous blood tissue was collected from 
the Department of Neurosurgery and Department of Pathology, University Hospital “Sisters 
of Charity”, Zagreb, Croatia. The metastasis tissue was frozen in liquid nitrogen and 
transported to the laboratory, where it was immediately transferred at -75C. The peripheral 
blood sample was collected in EDTA and processed immediately.  
The local Ethical Committee approved our study and the patient gave his informed 
consent. 
 Approximately 0.5 g of tumor tissue was homogenized with 1 ml extraction buffer (10 
mM Tris HCl, pH 8.0; 0.1 M EDTA, pH 8.0; 0.5% sodium dodecyl sulfate) and incubated 
with proteinase K (100 g/ml; Sigma, USA; overnight at 37C). Phenol chloroform extraction 
and ethanol precipitation followed.  
 Blood was used to extract leukocyte DNA. Five ml of blood was lysed with 7 ml 
distilled water and centrifuged (15 min/5000 g). The pellet was then processed as for DNA 
extraction from the tissue samples. 
Polymerase chain reaction 
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To amplify fragment of the exon 15 of the APC gene we used in a volume of 50 l: 5 
pmol of each primer (5-ATGATGTTGACCTTTCCAGGG-3 and 5-
CTTTTTTGGCATTGCGGAGCT-3), 200 ng template DNA, 5 l 10X buffer II, 1.5 mM 
MgCl2, 2.5 mM of each dNTP, 1 l (5 U) of Taq polymerase. PCR conditions were: initial 
denaturation, 5 min/95C; denaturation, 30 s/95C; annealing, 30 s/57C; extension, 45+1 
s/72C; final extension, 72C/7 min; 30 cycles. The PCR products were analyzed on 2% 
agarose gels. 
Sequencing 
PCR products were separated by agarose gel electrophoresis and visualized by 
ethidium bromide staining. DNA fragments were cut out and isolated from agarose gel 
(QIAquick gel extraction Kit, QIAGEN, Hilden, Germany). Sequencing reactions were 
performed with appropriate primers in a BigDye Terminator v1.1, Applied Biosystems, Foster 
City, USA, and analyzed on ABI PRISM 310. All sequences were confirmed by bidirectional 
sequencing of PCR products generated by at least two independent reactions. The sequencing 
of the observed sequence alteration in metastasis was repeated after Msp I restriction fragment 
length polymorphism (RFLP) allele separation. The allelic band suspected to be mutated was 
extracted from the gel and sequenced separately.  
Restriction fragment length polymorphism (RFLP)  
The exon 15 of APC gene was also investigated on the basis of RFLP of the PCR 
products, since the mutation was observed in an Msp I polymorphic site. The amplified 
fragment of exon 15 is 550 bp long and is cleaved with the Msp I endonuclease to two 250 bp 
fragments if the restriction site is present. Heterozygous patients demonstrated two bands 
(550+250 bp). PCR aliquots from metastasis and blood (10-15 l) were digested with 6 U 
Msp I (Gibco, USA, overnight at 37C) and were electrophoresed on 2.5% agarose gels 
and/or Spreadex gels (Elchrom scientific, Switzerland).  
Immunohistochemistry 
Immunohistochemistry was performed in order to determine the presence of APC 
protein in our sample. The sample was formalin-fixed, paraffin embedded, and 4-mm thick 
sections were placed on Capillary gap microscope slides (DakoCytomation, Denmark). The 
sections were immunostained using the biotin–avidin–horseradish peroxidase method as 
described previously [13]. The primary antibodies at optimized dilutions were applied for 30 
min at room temperature. The antibodies used for APC protein detection were: APC-1 
monoclonal mouse anti-human antibody that recognizes amino terminal epitope (diluted 1:50) 
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(Calbiochem, USA) and APC-2 monoclonal rabbit anti-human antibody (ready-to-use) that 
recognizes carboxy terminal epitope (Spring Bioscience, USA). Monoclonals used for β-
catenin detection were: monoclonal mouse anti-human antibody (diluted 1:200) from Dako 
Corporation, USA. All chemicals were from DakoCytomation. Negative controls were 
samples that underwent same staining procedure with the exclusion of the primary antibodies. 
Normal skin served as positive control. Two independent observers, i.e. blinded pathologists, 
experts in the field on an Olympus BH-2 microscope, performed the analysis of the labeling. 
 
Case Report 
A 49-year-old male patient from Osijek in continental Croatia with brain metastasis 
(carcinoma metastaticum cerebri regionis parietalis sinistrae) was admitted to our hospital 
due to operative procedure of the brain tumor lesion. The metastasis infiltrated the dura. 
Using magnetic resonance imaging (MRI) a tumor lesion was found in the left parietal region.  
During the operative procedure the tumor was maximally reduced using a microneurosurgical 
technique. Pathologist provided the histopathological diagnosis of metastasis. The diagnosis 
of the primary tumor from which the metastasis originated was established during the 
patient’s first visit to the hospital in January 2003. The chest radiograph and chest computed 
tomography (CT) scan revealed a large mass in the right upper lobe bronchus with bilateral 
mediastinal lymph node swelling which was confirmed by bronchoscopic examination. 
Biopsies were taken and histological evaluation revealed a small cell lung carcinoma (SCLC). 
At his first visit the patient was already stage IV (T4N2M1), but was in good physical 
condition. Laboratory findings were normal. CT scan revealed metastases in the lymph nodes 
and skin of the neck, in the bone, in the mediastinal lymph nodes, and brain. The patient had 
no family history of tumors but was a habitual smoker. He was started on chemotherapy with 
adriamycine (100 mg i.v.), endoxane (1000 mg i.v.), oncovine (1 mg i. v.) and zofran (8 mg 
i.v.) followed by further radiotherapy. The first response to the therapy was evaluated as good 
partial response. Altogether the patient was given three courses of the same combination of 
chemotherapy that was administered in his first visit. In September 2003 chemotherapy 
treatment was not successful. The patient was admitted to the hospital in May 2004 after 
which followed cerebral coma, and respiratory arrest.   
The results of DNA sequencing of the PCR product from the metastasis revealed a G 
to A change at position 5883, codon 1961 (Figure 1A). At the first sequencing attempt the 
single base substitution G/A was visible only when sequencing was performed in one 
direction, i.e. with one primer. The nucleotide sequence of the other allele was impairing the 
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analysis. Therefore, we suspected that only one allele was hit with the mutation. We decided 
to separate the alleles from the total PCR volume of 50 L and to sequence them separately. 
After this procedure it was obvious that one allele had CCAG while the other retained CCGG 
sequence. Both alleles from the autologous blood sample had CCGG sequence as shown in 
the result of sequencing (Figure 1B).    
The mutation was confirmed by RFLP analysis using Msp I endonuclease, since the 
mutation strikes the Msp I restriction site. The analysis of Msp I polymorphic site in APC’s 
exon 15 of our proband's blood sample showed that the patient was homozygous for this 
polymorphism, i.e. both alleles had CCGG Msp I restriction site and only one band appeared 
on the gel. In contrast to this our metastasis sample showed an additional band (550+250 bp) 
(Figure 2). This finding led us to conclude that our sample comprised a mutation in the 
polymorphic site in exon 15 of the APC gene. 
 
Discussion 
Exon 15 starts at nucleotide 1958, and is 6577 bp long [18]. After direct sequencing 
the fragment of exon 15, we found that the sequence at codon 1961 (position 5883) changed 
in metastasis tissue in CCAG. Since the change affected only one allele the digestion resulted 
in two bands. We, therefore, separately sequenced alleles from metastasis tissue, and 
confirmed that the uncut allele had the above mentioned substitution.  
Since CCG codes for proline, and CCA codes for the same amino acid, it is possible 
that our silent mutation has no functional consequences. On the other hand, the silent 
mutation present in the metastasis sample and not found in the constitutive DNA of the same 
patient may indicate an important regulatory element change at the DNA level. Different 
single-base substitutions in APC exons need to be evaluated not only by the predicted change 
in amino acid sequence, but rather at the nucleotide level itself. The introduction of a novel 
splice site is one explanation.  
Heinimann and co-authors [19] reported on mutations within regulatory elements of 
the APC gene. These authors also found many silent mutations within the exon 15 of the APC 
gene. Although they categorized the silent mutations as nonpathogenic polymorphisms they 
did not exclude their possible effects on transcription and splicing efficiency. Montera and co-
authors [20] report on a silent mutation in exon 14 of the APC gene that causes exon skipping. 
They stress the importance of investigating the significance of silent mutations. According to 
those findings new models of mutation consequences via changes in exonic regulatory 
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elements are proposed. Recent studies indicate that efficient splicing requires sequence 
elements distinct from the splice sites. These elements may affect splice site recognition 
during constitutive and alternative splicing. They are found within coding exons and are 
called exonic splicing enhancers (ESE) [21]. A silent genomic DNA variation might modulate 
the splicing and affect RNA. 
Silent mutations not leading to amino acid changes are generally considered to be 
normal variants, and are thought to have no role in disease. However, exonic silent mutations 
that are able to induce exon skipping have been described in association to the diseases in 
MLH1 [22], fibrilin-1 [23] and human phenylalanine hydroxylase genes [24]. 
Aretz and co-workers [1] revealed the importance of rare exonic single-base 
substitutions of APC gene that are predicted to result in silent (SNP) variants. The authors 
demonstrated that traditional functional consequence due exclusively to amino acid changes 
can no longer be regarded as the only responsible pathological event. Changes at the 
nucleotide DNA level are equally important. Silent mutations can affect classic consensus 
splice-site signals, can strike internal exonic sites such as ESE motifs, or introduce a novel 
cryptic, less active, in-frame splice site.  
In our case, this assumption is additionally strengthened by immunostaining that 
showed the lack of APC protein expression in our sample. We can speculate that APC protein 
was absent by inactivation of both alleles of the APC gene. One allele could be deleted at 
another gene locus, and the remaining one might have suffered from point mutation or a small 
deletion. Another possible explanation of the APC protein absence is the instability of the 
corresponding mRNA or truncated protein. This finding is in accordance with Kartheuser et 
al. [25] who report on a rare 3' exon 15 APC mutation at nucleotide 5960delA that was 
predicted to lead to a truncated protein of about 220 kDa. However, the western blot analysis 
they performed failed to show a truncated protein. The same result was also obtained by van 
der Liujt et al. [26].  
Contrary to APC protein status, beta-catenin was present in metastasis tissue and 
located in the nuclei of the majority of the cells. This finding is logical since APC acts as a 
negative regulator of wnt signaling, and is a critical component of the beta-catenin destruction 
machinery leading to the proteasome. In response to wnt signaling, or under the circumstances 
of mutated or missing APC, beta-catenin is stabilized, accumulates in the cytoplasm, and 
enters the nucleus where it activates the expression of target genes, among others, c-myc and 
cyclin D1 [12]. Our finding on beta-catenin’s nuclear staining in metastasis derived from lung 
cancer may be indicative of beta-catenin’ oncogenic activity. 
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The nucleotide position of the detected mutation is located in the central region of the 
APC protein that contains a series of seven 20-amino acid repeat motifs that bind beta-
catenin. The majority of truncated mutant proteins lack all or most of the 20-amino acid 
repeats, suggesting that this area is a target for elimination during tumorigenesis [3, 9] 
Recent research found beta-catenin mutations in a small subset of human and rat lung 
carcinomas, suggesting the involvement of the Wnt pathway in lung tumorigenesis [17]. 
Although LOH of the APC gene is a common finding in lung cancer, point mutations of this 
tumor suppressor have not been frequent [14, 15]. Contrary to the previous reports, novel 
findings indicate the presence of point mutations of the APC gene in lung cancers. Oghaki et 
al, [16] found two somatic mutations in squamous cell carcinoma, a 2-bp deletion in codon 
1465, and a missense mutation in codon 1317. The same authors also recorded one case of 
small cell lung carcinoma with somatic missense mutation in codon 1284. They also found 
nuclear beta-catenin staining in the mutated SCLC.  
In our opinion silent mutations should also be incorporated in mutation detection rate 
and validation. We wanted to inform you on this silent mutation which may contribute to a 
better understanding of the brain metastasis genetic profile.  
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Figure descriptions 
 
 
Figure 1. Sequence for the exon 15 of the APC gene. 550 bp fragment was sequenced with 
appropriate primers, and analyzed on ABI PRISM 310. (A) metastasis DNA, forward and 
reverse. (B) autologous lymphocyte DNA, forward and reverse. The arrow points to the 
mutant nucleotide. 
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Figure 2. (A) RFLP/MspI of APC gene's exon 15. Lane 1, molecular marker (100 bp ladder); 
lane 2, brain metastasis sample; lane 3, corresponding blood sample. 
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Figure 3. Brain metastasis immunohistochemically stained for detection of (A) APC protein. 
Patient was negative for the expression of APC protein when tested both with Ab-1 
(monoclonal mouse anti-human antibody, Calbiochem, USA) that recognizes the amino 
terminus, and with Ab-2 (monoclonal rabbit anti-human antibody, Spring Bioscience, USA) 
that recognizes the carboxy terminus; (B) positive control for APC detection; (C) beta-catenin 
protein. Patient with brain metastasis demonstrating nuclear localization of beta-catenin tested 
with monoclonal mouse anti-human antibody (Dako Corporation, USA).  
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